Antiva Biosciences is a clinical stage biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by Human Papilloma Virus (HPV) infection. These diseases include Cervical Intraepithelial Neoplasia  (CIN), Anal Intraepithelial Neoplasia (AIN), and Vulvar Intraepithelial Neoplasia (VIN). The lead medicine was developed at UC San Diego in the lab of Dr. Karl Hostetler, founder of Vical (VICL), Triangle Therapeutics (acquired by Gilead), and Chimerix (CMRX).